SBIR-STTR Award

Greatly Extended Subzero Ischemic Storage of Renal Allografts Using Novel Bio-inspired Next Generation Cryoprotectants
Award last edited on: 2/13/2024

Sponsored Program
SBIR
Awarding Agency
NIH : NIDDK
Total Award Amount
$971,228
Award Phase
1
Solicitation Topic Code
847
Principal Investigator
Mark A Kline

Company Information

X-Therma Inc

2600 Hilltop Drive Suite B220
Richmond, CA 94806
   (716) 861-150
   info@x-therma.com
   www.x-therma.com
Location: Single
Congr. District: 13
County: Alameda

Phase I

Contract Number: 2023
Start Date: ----    Completed: 8/1/2023
Phase I year
2023
Phase I Amount
$971,228
Organ preservation remains a daunting challenge. Organ specific ischemia windows of 4-24h greatly limit the field of organ transplantation to save lives and cause severe geographic restriction in the US and globally. However, by halting ischemic damage at the point of procurement, we could facilitate enhanced graft viability and thus faster patient recovery, drastically shorter hospital stays, and greatly diminished healthcare costs - all while tackling the biggest challenge of all - to increase the amount of available organs for transplant. The goal of this Direct-to-PhaseII SBIR proposal is to establish the pre-clinical use of XT-ViVo for the non- frozen, subzero ischemic preservation and transplantation of renal allografts leading to improved outcome in comparison to static cold storage and to render greatly extended CIT of up to 120h possible using practical storage and transport methods. Reducing damage during extended ischemia is of critical relevance to kidney transplantation. Indeed, the FDA has recognized this technology as a Breakthrough Device for up to 120h preservation of the kidney, which could lead to dynamic shifts to logistics of kidney transplantation. This project combines novel chemistry and expertise in tissue and organ preservation with world leaders in transplantation. We will apply novel cryoprotectants to high subzero temperature ischemic preservation of porcine kidneys followed by subsequent transplantation in an effort to significantly extend the ischemia window of human-sized organs in a clinically relevant model. The evaluation of innovative modalities that may transform current preservation strategies requires the use of translational animal models for reliable assessment of tissue viability and functional recovery post-preservation. Herein, we propose two primary aims of the proposed work. Advanced cryoprotectants will be synthesized and prepared into formulations as organ preservation solutions. The novel cryoprotectants will first be applied to the preservation of pig kidneys ex vivo, at subzero temperature. We will assess kidney survival, function, injury biomarkers, histology, and immunohistochemistry. This work will further asses the ability to greatly extend subzero ischemia time of the kidney up to 120h first ex vivo, and then using a widely-accepted preclinical large animal transplantation model for close clinical relevance to humans. Heterotopic kidney transplantation will be investigated after greatly extended ischemic storage on SLA-defined miniature swine. Animal survival and kidney function will be assessed similarly with a heightened level of detail at post-operative day 0, 1, 7, and 30 to assess both intermediate and long-term kidney function. Execution of the stated aims could result in a fundamental improvement in the field of organ transplantation and will aid acquisition of the final data set required prior to clearance and clinical for commercialization. The product will offer extension of the ischemia window, simplified use with minimal disruption of current practice, and strong cost competitiveness compared to the advanced organ perfusion systems being developed in the market today.

Public Health Relevance Statement:
Project narrative Organ preservation, storage, and transport technology is of paramount importance to the field of organ transplant and plays a lifesaving role, yet organ transplantation still suffers from very narrow time windows for organ transport. If preservation techniques could be sufficiently advanced, more time would be available to improve the allocation of donated organs leading to reduced geographic restriction, faster patient recovery, drastically shorter hospital stays, and greatly diminished healthcare costs - all while tackling the biggest challenge of all - to increase the amount of available organs for transplant and improve patient outcomes. This proposal aims to further develop organ storage technology to extend the time with which kidneys can be transported and successfully transplanted.

Project Terms:
Protocols documentation; Protocol; System; kidney allograft; renal allograft; Surgeon; success; kidney preservation; Recovery of Function; functional recovery; Animal Model; Animal Models and Related Studies; model of animal; Toxic effect; Toxicities; Peptoids; novel; Modality; Modeling; Property; Tissue Viability; Organ Size; Preservation Technique; in vivo; Patient-Focused Outcomes; Patient outcome; Patient-Centered Outcomes; patient oriented outcomes; Small Business Innovation Research Grant; SBIR; Small Business Innovation Research; Monitor; Process; Renal Blood Flow; pre-clinical; preclinical; cost; next generation; innovate; innovative; innovation; clinical relevance; clinically relevant; commercialization; bio-markers; biologic marker; biomarker; Biological Markers; Formulation; improved outcome; preservation; transplant model; post-transplantation; posttransplant; posttransplantation; post-transplant; Breakthrough device; Animals; Back; Dorsum; Blood Chemical Analysis; Blood Chemical Analyses; blood chemistry; Blood donor; Chemistry; Complete Blood Count; Creatinine; Cryopreservation; Cryofixation; cold preservation; cold storage; Dimethyl Sulfoxide; DMSO; Demasorb; Demeso; Dimethylsulphinyl; Dimethylsulphoxide; Domoso; Dromisol; Flushing; Geography; Goals; Histology; Human; Modern Man; Immunohistochemistry; Immunohistochemistry Cell/Tissue; Immunohistochemistry Staining Method; Ischemia; Kidney; Kidney Urinary System; renal; Kidney Transplantation; Kidney Grafting; Kidney Transplants; Renal Grafting; Renal Transplantation; Renal Transplants; kidney tx; Length of Stay; Number of Days in Hospital; hospital days; hospital length of stay; hospital stay; Marketing; Methods; Organ Preservation; Organ Transplantation; Grafting Procedure; Organ Transplants; organ allograft; organ graft; organ xenograft; Patients; Perfusion; Play; Postoperative Period; Post-Operative; Postoperative; Production; Proteins; Recommendation; Reperfusion Therapy; reperfusion; Role; social role; medical schools; medical college; school of medicine; Family suidae; Pigs; Suidae; Swine; porcine; suid; Miniature Swine; Minipigs; mini pig; mini-swine; miniswine; Technology; Temperature; Testing; Time; Tissue Preservation; Translating; Transplantation; transplant; Autologous Transplantation; Autograft; Autotransplant; autologous graft; autotransplantation; Universities; Urine; Weight; weights; Wisconsin; Work; Health Costs; Healthcare Costs; Health Care Costs; Data Set; kidney injury; renal injury; Injury to Kidney; injuries; Injury; Organ; Tissue Preservation Solutions; Organ Preservation Solutions; improved; Clinical; Phase; Rewarming; Chemicals; Evaluation; Blood Serum; Serum; kidney function; Renal function; Recovery; Logistics; Funding; Collaborations; Life; Investigation

Phase II

Contract Number: 1R44DK136396-01A1
Start Date: 5/31/2025    Completed: 00/00/00
Phase II year
----
Phase II Amount
----